The Global Antibiotic Research & Development Partnership

The Global Antibiotic Research & Development Partnership (GARDP) was established in May 2016 as a joint initiative by the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi). As an important element of the WHO Global Action Plan on Antimicrobial Resistance, this not-for-profit research and development (R&D) initiative addresses global public health needs by developing and delivering new or improved antibiotic treatments while endeavouring to ensure sustainable access.


REVIVE is a space for everybody with an interest in antimicrobial R&D. Researchers and drug developers can connect with each other and with world-class experts from the golden age of antibiotic development.

Collaborative Drug Discovery (CDD vault)

The CDD Vault is a hosted biological and chemical database that securely manages your private and external data.

Center for Molecular Biophysics

The UT/ORNL Center for Molecular Biophysics exists since 2006. The Center perform research at the interface of biological, environmental, physical, computational and neutron sciences.

Center for Disease Dynamics, Economics & Policy

CDDEP produces independent, multidisciplinary research to advance the health and wellbeing of human populations in the United States and around the world.

European Gram Negative Antibacterial Engine (ENABLE)

The ENABLE consortium is working to advance the development of promising new antibiotic compounds targeting Gram-negative bacteria such as Escherichia coli. The goal of the project is to develop attractive antimicrobial candidates for extensive preclinical studies and  First-in-Human clinical trials, bringing new antibiotics to treat Gram-negative infections one step closer to patients.